On Tuesday, Shares of Philip Morris International Inc. (NYSE:PM), lost -0.34% to $78.64.
Philip Morris International, declared that on August 11, 2015, PT HM Sampoerna Tbk. (“Sampoerna”), an indirect partner of Philip Morris International Inc. in which PMI holds a 98.18% interest through PT Philip Morris Indonesia (“PMID”), filed a registration statement with the Indonesian Financial Services Authority (Otoritas Jasa Keuangan or “OJK”), in connection with a potential rights issue (the “Rights Issue”) by Sampoerna. The purpose of the potential Rights Issue would be to comply with the Indonesian Stock Exchange’s (“IDX”) mandatory requirement of a minimum threshold for public shareholding. Following IDX regulations, all listed public companies are required to have at least 7.5% of their total paid-up capital owned by the public (not taking into account controlling or principal shareholders) by January 30, 2016. As advised by Sampoerna on its website on September 21, 2015, the price range for a potential institutional placement of rights shares in connection with the Rights Issue has been set at between Rp. 65,000 and Rp. 77,000 per rights share of Sampoerna. It is predictable that after the Rights Issue 7.50% of Sampoerna’s total paid-up capital will be owned by the public, in compliance with IDX requirements. Final pricing for the placement is predictable to occur on or about October 1, 2015.
Philip Morris International Inc., through its auxiliaries, manufactures and sells cigarettes, other tobacco products, and other nicotine-containing products. Its portfolio of brands comprise Marlboro, Merit, Parliament, Virginia Slims, L&M, Chesterfield, Bond Street, Lark, Muratti, Next, Philip Morris, and Red & White.
Shares of Jabil Circuit, Inc. (NYSE:JBL), inclined 1.80% to $22.04, during its last trading session.
Jabil Circuit, Inc. (JBL), declared preliminary, unaudited financial results for its fourth quarter and full fiscal year, ended August 31, 2015. The company stated fourth quarter net revenue of $4.7 billion and fiscal year net revenue of $17.9 billion.
Fiscal 2015 Financial Highlights
- Total Company revenue of $17.9 billion, an improvement of 14% year-over-year.
- Diversified Manufacturing Services revenue: $7.1 billion, an improvement of 39% year-over-year.
- Electronics Manufacturing Services revenue: $10.8 billion, an improvement of 1% year-over-year.
- Generated $1.24 billion in cash flow from operations.
- Returned about $150 million to shareholders via dividend and share repurchases.
Jabil Circuit, Inc., together with its auxiliaries, provides electronic manufacturing services and solutions worldwide. It offers electronics design, production, and product administration services to companies in the aerospace, automotive, computing, defense, digital home, energy, healthcare, industrial, instrumentation, lifestyles, mobility, mold, networking, packaging, peripherals, storage, telecommunications, and wearable technology industries.
At the end of Tuesday’s trade, Shares of Invesco Ltd. (NYSE:IVZ), lost -0.26% to $30.84.
Invesco PowerShares Canada, declared the September 2015 distributions for its exchange-traded funds (ETFs) listed on the Toronto Stock Exchange (TSX). Unit holders of record on September 29, 2015 will receive cash distributions payable on October 7, 2015.
Invesco Ltd. is a publicly owned investment manager. The firm provides its services to retail clients, institutional clients, high-net worth clients, public entities, corporations, unions, non-profit organizations, endowments, foundations, pension funds, financial institutions, and sovereign wealth funds. It manages separate client focused equity, balanced, and fixed income portfolios.
Finally, Array Biopharma Inc (NASDAQ:ARRY), ended its last trade with -4.60% loss, and closed at $4.56.
Clinical trial results from Array BioPharma’s (Nasdaq: ARRY) wholly-owned MEK inhibitor, binimetinib, and BRAF inhibitor, encorafenib, were presented this weekend at the European Society of Medical Oncology’s (ESMO) annual European Cancer Conference (ECC). At the meeting, preliminary data were shared from both a Phase 2 combination trial of binimetinib and encorafenib in BRAF-mutant melanoma patients (LOGIC2) and a Phase 1b/2 combination trial of binimetinib and ribociclib (Novartis, LEE011), a CDK4/6 inhibitor in NRAS-mutant melanoma patients.
Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
